Literature DB >> 18060036

IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland.

Pasquale Sansone1, Gianluca Storci, Simona Tavolari, Tiziana Guarnieri, Catia Giovannini, Mario Taffurelli, Claudio Ceccarelli, Donatella Santini, Paola Paterini, Kenneth B Marcu, Pasquale Chieco, Massimiliano Bonafè.   

Abstract

High serum levels of IL-6 correlate with poor outcome in breast cancer patients. However, no data are available on the relationship between IL-6 and mammary stem/progenitor cells, which may fuel the genesis of breast cancer in vivo. Herein, we address this issue in the MCF-7 breast cancer cell line and in primary human mammospheres (MS), multicellular structures enriched in stem/progenitor cells of the mammary gland. MS from node invasive breast carcinoma tissues expressed IL-6 mRNA at higher levels than did MS from matched non-neoplastic mammary glands. In addition, IL-6 mRNA was detected only in basal-like breast carcinoma tissues, an aggressive breast carcinoma variant showing stem cell features. IL-6 treatment triggered Notch-3-dependent upregulation of the Notch ligand Jagged-1 and promotion of MS and MCF-7-derived spheroid growth. Moreover, IL-6 induced Notch-3-dependent upregulation of the carbonic anhydrase IX gene and promoted a hypoxia-resistant/invasive phenotype in MCF-7 cells and MS. Finally, autocrine IL-6 signaling relied upon Notch-3 activity to sustain the aggressive features of MCF-7-derived hypoxia-selected cells. In conclusion, these data support the hypothesis that IL-6 induces malignant features in Notch-3-expressing stem/progenitor cells from human ductal breast carcinoma and normal mammary gland.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18060036      PMCID: PMC2096439          DOI: 10.1172/JCI32533

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  59 in total

1.  Gene expression profiling of breast cell lines identifies potential new basal markers.

Authors:  E Charafe-Jauffret; C Ginestier; F Monville; P Finetti; J Adélaïde; N Cervera; S Fekairi; L Xerri; J Jacquemier; D Birnbaum; F Bertucci
Journal:  Oncogene       Date:  2006-04-06       Impact factor: 9.867

2.  Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.

Authors:  D Conze; L Weiss; P S Regen; A Bhushan; D Weaver; P Johnson; M Rincón
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 3.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

4.  A gender--dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity.

Authors:  M Bonafè; F Olivieri; L Cavallone; S Giovagnetti; F Mayegiani; M Cardelli; C Pieri; M Marra; R Antonicelli; R Lisa; M R Rizzo; G Paolisso; D Monti; C Franceschi
Journal:  Eur J Immunol       Date:  2001-08       Impact factor: 5.532

5.  Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma.

Authors:  Claudio Talora; Antonio F Campese; Diana Bellavia; Monica Pascucci; Saula Checquolo; Manuela Groppioni; Luigi Frati; Harald von Boehmer; Alberto Gulino; Isabella Screpanti
Journal:  EMBO Rep       Date:  2003-10-17       Impact factor: 8.807

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

7.  CYP2C and IL-6 expression in breast cancer.

Authors:  H Knüpfer; R Schmidt; D Stanitz; M Brauckhoff; M Schönfelder; R Preiss
Journal:  Breast       Date:  2004-02       Impact factor: 4.380

Review 8.  Geriatric oncology.

Authors:  Lodovico Balducci
Journal:  Crit Rev Oncol Hematol       Date:  2003-06       Impact factor: 6.312

Review 9.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Authors:  Mohit Trikha; Robert Corringham; Bernard Klein; Jean-François Rossi
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

Review 10.  Metalloproteinases: role in breast carcinogenesis, invasion and metastasis.

Authors:  M J Duffy; T M Maguire; A Hill; E McDermott; N O'Higgins
Journal:  Breast Cancer Res       Date:  2000-06-07       Impact factor: 6.466

View more
  350 in total

1.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Authors:  Lauren L C Marotta; Vanessa Almendro; Andriy Marusyk; Michail Shipitsin; Janina Schemme; Sarah R Walker; Noga Bloushtain-Qimron; Jessica J Kim; Sibgat A Choudhury; Reo Maruyama; Zhenhua Wu; Mithat Gönen; Laura A Mulvey; Marina O Bessarabova; Sung Jin Huh; Serena J Silver; So Young Kim; So Yeon Park; Hee Eun Lee; Karen S Anderson; Andrea L Richardson; Tatiana Nikolskaya; Yuri Nikolsky; X Shirley Liu; David E Root; William C Hahn; David A Frank; Kornelia Polyak
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.

Authors:  Zachary C Hartman; Xiao-Yi Yang; Oliver Glass; Gangjun Lei; Takuya Osada; Sandeep S Dave; Michael A Morse; Timothy M Clay; Herbert K Lyerly
Journal:  Cancer Res       Date:  2011-04-25       Impact factor: 12.701

Review 3.  Canonical and non-canonical Notch ligands.

Authors:  Brendan D'Souza; Laurence Meloty-Kapella; Gerry Weinmaster
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

Review 4.  Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells.

Authors:  Gaoliang Ouyang; Zhe Wang; Xiaoguang Fang; Jia Liu; Chaoyong James Yang
Journal:  Cell Mol Life Sci       Date:  2010-03-18       Impact factor: 9.261

Review 5.  Targeting Notch to target cancer stem cells.

Authors:  Antonio Pannuti; Kimberly Foreman; Paola Rizzo; Clodia Osipo; Todd Golde; Barbara Osborne; Lucio Miele
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

Review 6.  Targeting breast cancer stem cells.

Authors:  Suling Liu; Max S Wicha
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

7.  TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.

Authors:  Gianluca Storci; Pasquale Sansone; Sara Mari; Gabriele D'Uva; Simona Tavolari; Tiziana Guarnieri; Mario Taffurelli; Claudio Ceccarelli; Donatella Santini; Pasquale Chieco; Kenneth B Marcu; Massimiliano Bonafè
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

8.  Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro.

Authors:  Feray Kockar; Hatice Yildrim; Rahsan Ilikci Sagkan; Carsten Hagemann; Yasemin Soysal; Jelena Anacker; Ahmed Ayad Hamza; Dirk Vordermark; Michael Flentje; Harun M Said
Journal:  World J Clin Oncol       Date:  2012-06-10

9.  Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus.

Authors:  Anniek Zaalberg; Sara Moradi Tuchayi; Amir H Ameri; Kenneth H Ngo; Trevor J Cunningham; Jean-Pierre Eliane; Maia Livneh; Thomas D Horn; Ilana S Rosman; Amy Musiek; Milan J Anadkat; Shadmehr Demehri
Journal:  J Invest Dermatol       Date:  2018-07-17       Impact factor: 8.551

10.  Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Authors:  Joao Incio; Jennifer A Ligibel; Daniel T McManus; Priya Suboj; Keehoon Jung; Kosuke Kawaguchi; Matthias Pinter; Suboj Babykutty; Shan M Chin; Trupti D Vardam; Yuhui Huang; Nuh N Rahbari; Sylvie Roberge; Dannie Wang; Igor L Gomes-Santos; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Sara M Tolaney; Ian E Krop; Dan G Duda; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2018-03-14       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.